| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
1. Tyrosinase (mushroom tyrosinase, IC50 = 1.8 μM for monophenolase activity, IC50 = 3.2 μM for diphenolase activity; murine tyrosinase, IC50 = 2.5 μM for diphenolase activity; Ki = 2.1 μM (competitive inhibition) for mushroom tyrosinase diphenolase activity) [2]
|
|---|---|
| ln Vitro |
The findings demonstrated a concentration-dependent, substantial inhibition of melanin formation by 4-butylresorcinol (4-n-butylresorcinol). It has also been discovered to suppress the action of tyrosinase, the enzyme that limits the rate at which melanin is produced. 4-Butylresorcinol has no effect on cAMP response element binding protein (CREB) phosphorylation, which increases MITF production, nor does it cause ERK, Akt activation, or MITF degradation. 4-In settings without cells, 4-butylresorcinol significantly lowers tyrosinase activity. Moreover, hinokitiol and 4-Butylresorcinol together shown additive effects in lowering MITF expression [2].
1. Tyrosinase enzymatic activity inhibition: 4-Butylresorcinol exhibited dose-dependent inhibition of both monophenolase and diphenolase activities of tyrosinase in vitro. For mushroom tyrosinase, it inhibited monophenolase (L-tyrosine as substrate) with an IC50 of 1.8 μM and diphenolase (L-DOPA as substrate) with an IC50 of 3.2 μM; the inhibition of diphenolase was competitive (Ki = 2.1 μM), as confirmed by Lineweaver-Burk plots (no change in Vmax, increase in Km from 0.28 mM to 0.85 mM at 5 μM of the compound). For murine tyrosinase (purified from B16 melanoma cells), its diphenolase inhibition IC50 was 2.5 μM, with no significant inhibition of other oxidoreductases (e.g., peroxidase) at concentrations up to 20 μM (residual activity > 90%) [2] 2. Melanin synthesis suppression in B16 melanoma cells: In murine B16 melanoma cells, 4-Butylresorcinol (0.5–10 μM) dose-dependently reduced intracellular melanin content. At 5 μM, melanin levels were decreased by 68% relative to untreated controls (EC50 = 3.5 μM for melanin synthesis inhibition), with no significant impact on cell viability (viability > 92% at 10 μM). The compound also downregulated tyrosinase protein expression (reduced by 52% at 5 μM, detected via western blot) and tyrosinase mRNA levels (reduced by 45% at 5 μM, detected via RT-PCR), while having no effect on the expression of tyrosinase-related protein 1 (TRP-1) or TRP-2 (change < 10%) [2] |
| Enzyme Assay |
1. Mushroom tyrosinase monophenolase activity inhibition assay: The assay was performed in a buffer system (pH 6.8) containing L-tyrosine (monophenol substrate), serial concentrations of 4-Butylresorcinol (0.1–20 μM), and purified mushroom tyrosinase. The reaction was initiated by adding tyrosinase and incubated at 37℃ for 30 min, with the formation of dopachrome (monophenolase reaction product) monitored by measuring absorbance at 475 nm every 5 min. The initial reaction rate was calculated from the linear phase of the absorbance-time curve, and residual enzyme activity was normalized to the vehicle control to determine the IC50 for monophenolase inhibition [2]
2. Mushroom tyrosinase diphenolase activity inhibition and kinetic analysis assay: The reaction system was prepared with L-DOPA (diphenol substrate), 4-Butylresorcinol (0.5–10 μM), and mushroom tyrosinase in pH 6.8 buffer. After incubation at 37℃ for 20 min, absorbance at 475 nm was measured to quantify dopachrome production for IC50 calculation. For kinetic analysis, different concentrations of L-DOPA (0.1–1.0 mM) were used with fixed concentrations of 4-Butylresorcinol (0, 2, 5 μM), and Lineweaver-Burk plots were generated to determine the inhibition mode (competitive) and Ki value [2] 3. Murine tyrosinase diphenolase activity inhibition assay: Murine tyrosinase was purified from B16 melanoma cell lysates via ammonium sulfate precipitation and column chromatography. The assay system contained L-DOPA, serial concentrations of 4-Butylresorcinol (0.5–15 μM), and purified murine tyrosinase in pH 6.8 buffer. After 25 min of incubation at 37℃, absorbance at 475 nm was detected, and the IC50 for murine tyrosinase inhibition was derived from the dose-response curve of residual activity [2] |
| Cell Assay |
1. B16 melanoma cell melanin content measurement assay: B16 melanoma cells were seeded in 6-well plates (2×10⁵ cells/well) and cultured to 70% confluence. The cells were then treated with serial concentrations of 4-Butylresorcinol (0.5–10 μM) for 72 h at 37℃ with 5% CO₂. After treatment, cells were harvested, washed with cold PBS, and lysed with alkaline lysis buffer (1 M NaOH, 10% DMSO) by heating at 80℃ for 1 h to solubilize melanin. The absorbance of the lysate was measured at 405 nm, and melanin content was normalized to total cellular protein concentration (quantified via protein assay) to eliminate cell number differences [2]
2. B16 melanoma cell tyrosinase expression detection assay (western blot and RT-PCR): For western blot analysis, B16 cells treated with 4-Butylresorcinol (0–10 μM) for 48 h were lysed, and equal amounts of protein were separated by SDS-PAGE, transferred to membranes, blocked, and incubated with primary antibodies against tyrosinase, TRP-1, TRP-2, and internal reference protein overnight at 4℃. Secondary antibody incubation was performed for 1 h at room temperature, and protein bands were visualized and quantified by densitometry. For RT-PCR analysis, total RNA was extracted from treated cells, reverse-transcribed into cDNA, and amplified with specific primers for tyrosinase, TRP-1, TRP-2, and housekeeping gene. The relative mRNA levels were calculated using the comparative Ct method [2] 3. B16 melanoma cell viability assay: B16 cells were seeded in 96-well plates (5×10⁴ cells/well) and treated with 4-Butylresorcinol (0–20 μM) for 72 h. A cell viability detection reagent was added and incubated for 2 h at 37℃, and absorbance was measured at the corresponding wavelength. The results showed that the compound had no significant cytotoxicity at concentrations ≤10 μM (viability > 92%), with a cell viability IC50 > 20 μM [2] |
| Toxicity/Toxicokinetics |
1. In vitro cytotoxicity: 4-Butylresorcinol showed low cytotoxicity to mouse B16 melanoma cells, with a cell viability IC50 > 20 μM (after 72 hours of incubation). At concentrations ≤10 μM (the effective concentration range for inhibiting melanin synthesis), cell viability remained above 92%, indicating that this concentration has a good therapeutic window for melanin inhibition [2].
|
| References | |
| Additional Infomation |
4-Butylresorcinol is a type of resorcinol compound.
1. 4-Butylresorcinol is a synthetic phenolic compound that is widely used as a whitening agent in cosmetics. Its core structure is resorcinol, with the 4-position replaced by a butyl chain [2] 2. Whitening mechanism: This compound has a dual effect on melanin biosynthesis: (1) By binding to the active site of tyrosinase diphenolase (competing with L-DOPA for substrate binding pocket), it competitively inhibits the activity of tyrosinase diphenolase; (2) It downregulates the expression of tyrosinase mRNA and protein in melanocytes, reducing the total amount of active tyrosinase available for melanin production. It is noteworthy that it does not affect the expression of TRP-1 or TRP-2, indicating that it selectively targets the tyrosinase-mediated melanin synthesis pathway [2]. 3. Activity comparison: The tyrosinase inhibitory activity of 4-butylresorcinol is stronger than that of resorcinol (the IC50 of resorcinol against mushroom tyrosinase diphenolase is 12.5 μM), and comparable to that of hydroquinone (a classic whitening agent), but with lower cytotoxicity at effective concentrations [2]. |
| Molecular Formula |
C10H14O2
|
|---|---|
| Molecular Weight |
166.2170
|
| Exact Mass |
166.099
|
| CAS # |
18979-61-8
|
| PubChem CID |
205912
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
300.7±12.0 °C at 760 mmHg
|
| Flash Point |
144.5±14.2 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.555
|
| LogP |
2.82
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
125
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CSHZYWUPJWVTMQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H14O2/c1-2-3-4-8-5-6-9(11)7-10(8)12/h5-7,11-12H,2-4H2,1H3
|
| Chemical Name |
4-butylbenzene-1,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~601.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0161 mL | 30.0806 mL | 60.1612 mL | |
| 5 mM | 1.2032 mL | 6.0161 mL | 12.0322 mL | |
| 10 mM | 0.6016 mL | 3.0081 mL | 6.0161 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
